State of New Jersey Common Pension Fund D Trims Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

State of New Jersey Common Pension Fund D lessened its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 5.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 48,865 shares of the company’s stock after selling 3,039 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in CRISPR Therapeutics were worth $3,059,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Signaturefd LLC increased its position in CRISPR Therapeutics by 12.5% in the third quarter. Signaturefd LLC now owns 2,124 shares of the company’s stock worth $96,000 after buying an additional 236 shares in the last quarter. Itau Unibanco Holding S.A. increased its position in CRISPR Therapeutics by 10.8% in the third quarter. Itau Unibanco Holding S.A. now owns 2,521 shares of the company’s stock worth $114,000 after buying an additional 245 shares in the last quarter. Spire Wealth Management increased its position in CRISPR Therapeutics by 32.7% in the third quarter. Spire Wealth Management now owns 1,052 shares of the company’s stock worth $48,000 after buying an additional 259 shares in the last quarter. CWM LLC increased its position in CRISPR Therapeutics by 80.7% in the third quarter. CWM LLC now owns 582 shares of the company’s stock worth $26,000 after buying an additional 260 shares in the last quarter. Finally, WealthPlan Investment Management LLC increased its position in CRISPR Therapeutics by 3.1% in the fourth quarter. WealthPlan Investment Management LLC now owns 9,663 shares of the company’s stock worth $605,000 after buying an additional 288 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $53.91 on Friday. The stock has a 50 day moving average of $70.57 and a 200 day moving average of $63.95. CRISPR Therapeutics AG has a 12 month low of $37.55 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. During the same period in the previous year, the company posted ($1.41) earnings per share. CRISPR Therapeutics’s quarterly revenue was up 3253.3% on a year-over-year basis. As a group, analysts forecast that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 50,000 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the completion of the transaction, the chief executive officer now directly owns 187,377 shares of the company’s stock, valued at $11,338,182.27. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Samarth Kulkarni sold 50,000 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $60.51, for a total value of $3,025,500.00. Following the sale, the chief executive officer now directly owns 187,377 shares in the company, valued at $11,338,182.27. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, General Counsel James R. Kasinger sold 1,913 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the sale, the general counsel now owns 57,371 shares in the company, valued at $4,570,747.57. The disclosure for this sale can be found here. Over the last three months, insiders sold 133,992 shares of company stock valued at $9,157,835. Insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CRSP. Barclays upped their price target on CRISPR Therapeutics from $61.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 22nd. TheStreet upgraded CRISPR Therapeutics from a “d+” rating to a “c” rating in a research report on Friday, February 23rd. Mizuho upped their price target on CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Citigroup upped their price objective on CRISPR Therapeutics from $88.00 to $89.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. Finally, Chardan Capital upped their price objective on CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $76.29.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.